Baillie Gifford & Co. Purchases 31,773 Shares of BioNTech SE (NASDAQ:BNTX)

Baillie Gifford & Co. boosted its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 0.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,308,071 shares of the company's stock after acquiring an additional 31,773 shares during the quarter. Baillie Gifford & Co. owned 3.49% of BioNTech worth $986,750,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in BioNTech in the third quarter valued at $373,000. Arlington Capital Management Inc. grew its position in BioNTech by 46.4% in the 3rd quarter. Arlington Capital Management Inc. now owns 3,807 shares of the company's stock worth $452,000 after purchasing an additional 1,207 shares in the last quarter. Lodestone Wealth Management LLC bought a new stake in BioNTech in the 3rd quarter worth about $8,373,000. Caas Capital Management LP boosted its stake in BioNTech by 145.4% in the third quarter. Caas Capital Management LP now owns 17,190 shares of the company's stock valued at $2,042,000 after acquiring an additional 10,185 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in BioNTech by 457.9% in the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock valued at $25,900,000 after acquiring an additional 178,981 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Trading Down 1.6 %

BNTX stock traded down $1.69 during trading on Tuesday, reaching $107.04. 256,189 shares of the stock traded hands, compared to its average volume of 785,593. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The business's 50 day moving average price is $112.26 and its 200-day moving average price is $96.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.40. The firm has a market capitalization of $25.45 billion, a PE ratio of -51.78 and a beta of 0.26.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the company posted $0.73 EPS. As a group, sell-side analysts forecast that BioNTech SE will post -3.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Hsbc Global Res upgraded shares of BioNTech from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 2nd. Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Bank of America raised their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $125.00 to $124.00 and set a "neutral" rating for the company in a research report on Monday, November 4th. Finally, HC Wainwright raised their price objective on shares of BioNTech from $113.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, October 7th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $137.54.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.